Carvedilol controlled-release - Chong Kun Dang

Drug Profile

Carvedilol controlled-release - Chong Kun Dang

Alternative Names: Carvedilol sustained-release - Chong Kun Dang; CKD-825; Dilatrend SR

Latest Information Update: 05 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chong Kun Dang
  • Class Antihypertensives; Carbazoles; Ethanolamines; Heart failure therapies; Ischaemic heart disorder therapies; Phenyl ethers; Propanolamines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha beta adrenergic receptor antagonists; Beta-adrenergic receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Angina pectoris; Essential hypertension; Heart failure

Most Recent Events

  • 30 Sep 2013 Chong Kun Dang completes a phase III trial in Essential hypertension in South Korea (NCT01756430)
  • 30 May 2013 Biomarkers information updated
  • 01 Feb 2013 Launched before February 2013 for Angina pectoris in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top